Karen L. Smith

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Dublin L2 4, Ireland
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Alex Levit, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Karen L. Smith

Form 4 holding EVP, Chief Medical Officer

Emergent BioSolutions Inc.

Security class
Common Stock
Shares / value
11,888
Estimated value
$21,636
Report date
07 May 2021
Price
$1.82
Ownership
Direct
Form 4 holding Chief Medical Officer

Quince Therapeutics, Inc.

Security class
Employee Stock Option (right to buy)
Shares / value
225,000
Estimated value
Report date
01 Feb 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Skye Bioscience, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
75,000
Estimated value
Report date
31 Mar 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Talaris Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
20,500
Estimated value
Report date
13 Jun 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Aurinia Pharmaceuticals Inc.

Security class
Director Stock Option (right to buy)
Shares / value
18,641
Estimated value
Report date
21 Nov 2024
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Director

ACCELERON PHARMA INC

Security class
Common Stock
Shares / value
0
Estimated value
Report date
19 Nov 2021
Price
$29.37
Ownership
Direct
Form 4 holding Director

ACCELERON PHARMA INC

Security class
Option to Purchase Common Stock
Shares / value
0
Estimated value
Report date
19 Nov 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

ANTARES PHARMA, INC.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
24 May 2022
Price
$5.60
Ownership
Direct
Form 4 holding Director

ANTARES PHARMA, INC.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
24 May 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Aurinia Pharmaceuticals Inc.

Security class
Restricted Stock Units
Shares / value
0
Estimated value
Report date
08 Nov 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Karen L. Smith

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .